MarketScreener Homepage > Equities > London Stock Exchange > Dechra Pharmaceuticals PLC DPH GB0009633180

Report

Delayed London Stock Exchange - 01/25 11:35:03 am
3716	GBX		+1.20%

01/14

DECHRA PHARMACEUTICALS : On Track to Surpass FY21 Estimates As Interim Revenue Grows 21%

2020

DECHRA PHARMACEUTICALS PLC : Ex-dividend day for final dividend

2020

DECHRA PHARMACEUTICALS : Preliminary Results Presentation for the year ended 30 June 2020

Summary

Quotes 5-day view Delayed Quote.

Delayed London Stock Exchange

01/19/2021	01/20/2021	01/21/2021	01/22/2021	01/25/2021	Date
3662(c)	3664(c)	3648(c)	3672(c)	3716(c)	Last
163 034	233 089	262 115	145 420	344 765	Volume
+0.49%	+0.05%	-0.44%	+0.66%	+1.20%	Change

More quotes

Financials

Sales 2021	576 M 786 M 786 M
Net income 2021	47,1 M 64,3 M 64,3 M
Net Debt 2021	165 M 226 M 226 M
P/E ratio 2021	88,9x
Yield 2021	1,00%

Sales 2022	621 M 848 M 848 M
Net income 2022	59,4 M 81,1 M 81,1 M
Net Debt 2022	94,5 M 129 M 129 M
P/E ratio 2022	71,1x
Yield 2022	1,08%

Capitalization	4 019 M 5 486 M 5 487 M
EV / Sales 2021	7,27x
EV / Sales 2022	6,62x
Nbr of Employees	-
Free-Float	98,3%

More Financials

Company

Dechra Pharmaceuticals specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (70.6%); - food producing animal products (11.9%); - equine health products (7.2%); - animal feeds (6%); - other (4.3%): products manufactured by third parties. Net sales are distributed geographically as follows: the...

Sector

Pharmaceuticals

Calendar

02/22

Earnings Release

More about the company

Notations Surperformance© of Dechra Pharmaceuticals PLC

Trading Rating :

Investor Rating :

More Ratings

All news about DECHRA PHARMACEUTICALS PLC

01/14	DECHRA PHARMACEUTICALS : On Track to Surpass FY21 Estimates As Interim Revenue G..	MT
2020	DECHRA PHARMACEUTICALS PLC : Ex-dividend day for final dividend	FA
2020	DECHRA PHARMACEUTICALS : Preliminary Results Presentation for the year ended 30 ..	PU
2020	EUROPE : European shares kick of week on strong footing, vaccine progress eyed	RE
2020	European shares end higher for first time in three sessions	RE
2020	DECHRA PHARMACEUTICALS PLC : annual earnings release
2020	Elanco Animal Health wins approval to buy Bayer unit	RE
2020	DECHRA PHARMACEUTICALS PLC : Monthly statement on outstanding equity shares and ..	CO
2020	DECHRA PHARMACEUTICALS PLC : Monthly statement on outstanding equity shares and ..	CO
2020	DECHRA PHARMACEUTICALS PLC : Monthly statement on outstanding equity shares and ..	CO
2020	KINDRED BIOSCIENCES : Announces Completion of Mirataz Transaction	AQ
2020	DECHRA PHARMACEUTICALS : Kindred Biosciences Announces Completion of Mirataz® (m..	PR
2020	DECHRA PHARMACEUTICALS PLC : Monthly statement on outstanding equity shares and ..	CO
2020	KINDRED BIOSCIENCES : Announces Mirataz Transaction and Reports Fourth Quarter a..	AQ
2020	DECHRA PHARMACEUTICALS : acquires worldwide rights to Mirataz (R)	PU

More news

News in other languages on DECHRA PHARMACEUTICALS PLC

2020	Déjà pliée, cette élection ?
2020	AVIS D'ANALYSTES DU JOUR : Air Liquide, Continental, Galapagos, Logitech, Superd..
2020	EN DIRECT DES MARCHES : Sanofi, Renault, Suez, Natixis, Solocal, AB Science, Tes..
2020	La baleine du Nasdaq ?
2020	DECHRA PHARMACEUTICALS PLC : publication des résultats annuels

More news

Provided by Scoopnest.com

Chart DECHRA PHARMACEUTICALS PLC

Duration : Period :

Dechra Pharmaceuticals PLC Technical Analysis Chart | DPH | GB0009633180 | MarketScreener

Full-screen chart

Technical analysis trends DECHRA PHARMACEUTICALS PLC

	Short Term	Mid-Term	Long Term
Trends	Bullish	Bullish	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	10
Average target price	3 598,00 GBX
Last Close Price	3 716,00 GBX
Spread / Highest target	14,4%
Spread / Average Target	-3,18%
Spread / Lowest Target	-24,7%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Ian David Page	Chief Executive Officer & Executive Director
William Anthony Rice	Non-Executive Chairman
Paul Sandland	Chief Financial Officer & Executive Director
Susan Longhofer	Chief Scientific Officer
Allen Mellor	Director-Information Technology

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

DECHRA PHARMACEUTICALS PLC	7.71%	5 486



ZOETIS	-1.31%	77 625
ELANCO ANIMAL HEALTH INCORPORATED	-0.68%	14 375
JINYU BIO-TECHNOLOGY CO., LTD.	2.39%	3 649
VIRBAC	-8.82%	2 259
VÉTOQUINOL SA	3.35%	1 288

More Results